PBTZ169

Catalog No.S6549 Synonyms: macozinone

For research use only.

PBTZ169 (macozinone), an antibiotic with antimycobacterial activity, is an irreversible inhibitor of DprE1.

PBTZ169 Chemical Structure

CAS No. 1377239-83-2

Selleck's PBTZ169 has been cited by 1 Publication

Purity & Quality Control

Choose Selective Bacterial Inhibitors

Biological Activity

Description PBTZ169 (macozinone), an antibiotic with antimycobacterial activity, is an irreversible inhibitor of DprE1.

Protocol (from reference)

Solubility (25°C)

In vitro

Chemical Information

Molecular Weight 456.48
Formula

C20H23F3N4O3S

CAS No. 1377239-83-2
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles C1CCC(CC1)CN2CCN(CC2)C3=NC(=O)C4=C(S3)C(=CC(=C4)C(F)(F)F)[N+](=O)[O-]

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT03776500 Completed Drug: PBTZ169|Drug: Placebo Tuberculosis Pulmonary Innovative Medicines for Tuberculosis|Bill and Melinda Gates Foundation February 21 2019 Phase 1
NCT03423030 Completed Drug: PBTZ169 Formulation|Drug: Placebo|Drug: PBTZ169 NCP Tuberculosis|Tuberculosis Pulmonary Innovative Medicines for Tuberculosis|Bill and Melinda Gates Foundation December 5 2017 Phase 1
NCT03334734 Terminated Drug: PBTZ169|Drug: Isoniazid Tuberculosis Nearmedic Plus LLC|OCT LLC December 16 2016 Phase 2

(data from https://clinicaltrials.gov, updated on 2022-08-01)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy PBTZ169 | PBTZ169 supplier | purchase PBTZ169 | PBTZ169 cost | PBTZ169 manufacturer | order PBTZ169 | PBTZ169 distributor